INABライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers...

Stats
本日の出来高	58 509.00
平均出来高	352 833
時価総額	43.69M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.170 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.010
ATR14	$0.00800 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Epperly Corinne	Buy	12 500	Stock Option (right to buy)
2024-02-07	Ho William Tai-wei	Buy	502 000	Employee Stock Option (right to buy)
2024-02-07	Goswami Trishna	Buy	176 000	Employee Stock Option (right to buy)
2024-02-07	Rochlin Kate	Buy	186 000	Employee Stock Option (right to buy)
2024-02-07	Lamb Lawrence	Buy	169 000	Employee Stock Option (right to buy)

INSIDER POWER
24.70
Last 98 transactions
Buy: 9 531 383 \| Sell: 5 834 681

ボリューム相関

長: 0.03 (neutral)

短: -0.36 (neutral)

Signal:(46.188) Neutral

IN8bio, Inc. 相関

10 最も正の相関
PCVX	0.832
DTSS	0.822
IMPL	0.82
SLM	0.816
AFYA	0.815
JAZZ	0.814
AVIR	0.811
PDSB	0.811
LIVN	0.806
GOEV	0.805

10 最も負の相関
PAE	-0.843
RAVN	-0.832
NEO	-0.828
ZGNX	-0.813
SERA	-0.813
PEGA	-0.81
ACVA	-0.81
EBAC	-0.809
ICON	-0.808
TA	-0.807

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

IN8bio, Inc. 相関 - 通貨/商品

-0.51
( weak negative )

-0.56
( weak negative )

0.00
( neutral )

-0.59
( weak negative )

0.00
( neutral )

0.57
( weak )

IN8bio, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2023
収益:	$0
総利益:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2022
収益:	$0
総利益:	$-1.10M (0.00 %)
EPS:	$-1.310

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.095

Financial Reports:

No articles found.

IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.